A new analysis published by Avalere Health found that the proposed GLOBE (Global Benchmark for Efficient Drug Pricing) Model would have a minimal impact on Medicare Part B beneficiaries’ out-of-pocket (OOP) costs.
Introduced by CMS in December 2025, the GLOBE Model would incorporate international reference pricing into Medicare Part B by comparing drug average sales prices to international benchmarks and adjusting rebates and cost sharing for a 25% sample of fee-for-service (FFS) beneficiaries. Avalere’s review shows that fewer than 7% of beneficiaries use the 62 eligible drugs and that nearly all have supplemental coverage, such as Medicaid, employer-sponsored insurance, or Medigap, that already offset the standard 20% Part B coinsurance. As a result, only about 0.3% of sampled beneficiaries would see any direct change in OOP liability. Learn more here.
Aimed Alliance continues to propose alternatives to international reference pricing that can more directly improve consumer affordability. Read Aimed Alliance’s Alternatives and Recommendations.
Last Updated on February 19, 2026 by Aimed Alliance
